Skip to content

TURP Outcome Prediction Calculator Study

Identification of Predictive Parameters for Developing a TURP Outcome Calculator for Preoperative Patient Assessment

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07277556
Acronym
TURP-SCORE
Enrollment
200
Registered
2025-12-11
Start date
2026-03-02
Completion date
2027-12-13
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia (BPH)

Keywords

BPH, LUTS, TURP, Uroflowmetry, IPSS, Outcome Prediction

Brief summary

The goal of this observational study is to identify which preoperative clinical, ultrasound, and uroflowmetry parameters can help predict the success of transurethral resection of the prostate (TURP) in adult male patients with symptomatic benign prostatic hyperplasia (BPH). The main questions it aims to answer are: Which preoperative parameters (IPSS, prostate volume, post-void residual urine, Qmax, comorbidities) are associated with successful postoperative outcomes? Can these parameters be used to develop a non-invasive calculator to estimate the likelihood of TURP success? Participants will undergo routine clinical evaluation that is part of standard care, including: * completion of the IPSS questionnaire * digital rectal examination * ultrasound measurement of prostate volume and residual urine * uroflowmetry (Qmax and voided volume) * standard laboratory testing Eligible participants will then undergo TURP as clinically indicated and return for postoperative assessments of symptom improvement and urinary flow parameters.

Detailed description

Benign prostatic hyperplasia (BPH) is a common condition in aging men and may lead to lower urinary tract symptoms (LUTS), subvesical obstruction, and related complications such as urinary retention, bladder stones, recurrent infections, and renal impairment. Transurethral resection of the prostate (TURP) remains the standard surgical treatment for symptomatic benign prostatic obstruction (BPO). However, a subset of patients, particularly those with an underlying hypocontractile detrusor, may not benefit from TURP and continue to experience significant voiding dysfunction after surgery. Since formal urodynamic pressure-flow studies are invasive, time-consuming, and resource-intensive, there is clinical value in identifying non-invasive predictors of surgical success. This prospective observational study will evaluate preoperative clinical, ultrasound, and uroflowmetry parameters associated with successful postoperative outcomes after TURP. Adult male patients with symptomatic BPH and an indication for TURP will undergo standardized assessment including medical history, IPSS questionnaire, digital rectal examination, serum PSA, ultrasound-determined prostate volume and post-void residual urine, and uroflowmetry parameters such as Qmax and voided volume. Comorbidities relevant to bladder function, including diabetes mellitus and neurological conditions, will be recorded. TURP will be performed according to standard clinical practice, and resected tissue will undergo routine histopathological evaluation. Postoperative follow-up will include IPSS reassessment, uroflowmetry, and ultrasound measurement of residual urine at one month and during subsequent routine evaluations. Surgical outcomes will be categorized as successful or unsuccessful based on subjective symptom improvement and objective urinary flow parameters. Using the collected data, the study will identify which preoperative variables correlate with favorable postoperative outcomes. These parameters will subsequently be used to inform the development of a predictive TURP outcome calculator. The anticipated value of this study is to support individualized clinical decision-making in patients with BPH, particularly those in whom the distinction between obstruction and impaired detrusor contractility is unclear. By identifying patients who are less likely to benefit from TURP based on non-invasive parameters, the resulting calculator may help reduce unnecessary procedures, avoid postoperative morbidity, and potentially limit the need for invasive urodynamic testing.

Interventions

None listed

Sponsors

General Hospital Sveti Duh
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum

Inclusion criteria

* Male patients aged 18 years or older * Clinical diagnosis of benign prostatic hyperplasia (BPH) * Indication for TURP based on symptoms or complications * Completed preoperative evaluation (IPSS, ultrasound, PSA, uroflowmetry) * Able to provide informed consent

Exclusion criteria

* Suspected or confirmed prostate cancer * No clinical evidence of BPH * Prior urodynamic diagnosis of underactive/neurogenic bladder * Prior prostate surgery * Inability to participate in follow-up

Design outcomes

Primary

MeasureTime frameDescription
Change in IPSS Score After TURP1 Month, 3 MonthsImprovement in lower urinary tract symptoms measured by the International Prostate Symptom Score (IPSS - validated questionnaire ranging from 0 to 35 points, where higher scores indicate more severe symptoms) one month after TURP compared to baseline.
Change in Qmax After TURP1 Month, 3 MonthsImprovement in maximum urinary flow rate (Qmax) measured by uroflowmetry after TURP
Change in Post-Void Residual Urine (PVR)1 Month, 3 MonthsReduction in ultrasound-measured residual urine after voiding following TURP
Change in Voided Volume on Uroflowmetry1 Month, 3 MonthsImprovement in total voided volume after TURP

Secondary

MeasureTime frameDescription
Composite Surgical Success Rate1 Month, 3 MonthsProportion of patients achieving predefined surgical success, based on combined improvements in IPSS, Qmax, voided volume, and post-void residual urine
Complication Rate Following TURP30 DaysFrequency of postoperative complications categorized using Clavien-Dindo classification of surgical complications ranging from Grade 1 to Grade V (Grade 1 representing minor deviations from the normal postoperative course and Grade V representing patient death)

Contacts

Primary ContactAdelina Hrkac, MD
adelina.surjan@gmail.com00385958146992

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026